Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients

Bertrand Lioger (1) , Soujanya Ratna Edupuganti , Denis Mulleman (2) , Christophe Passot (2) , Celine Desvignes (2) , Theodora Bejan-Angoulvant (2) , Gilles Thibault (2) , Valérie Gouilleux-Gruart (3) , Julien Mélet , Gilles Paintaud (2) , David Ternant (2)

1 Service de Médecine Interne
2 GICC UMR 7292 CNRS - Génétique, immunothérapie, chimie et cancer (GICC), UMR 7292 CNRS [2012-2017]
3 Développement normal et pathologique des lymphocytes et signalisation

Rituximab is a monoclonal antibody directed against CD20, which is approved in rheumatoid arthritis (RA). This study aimed at assessing the influence of CD19+ cell counts as target-antigen amount, and of immunoglobulin G (IgG) serum concentrations on rituximab pharmacokinetics in RA patients.

Keywords: elimination rate constant; immunoglobulin; pharmacokinetics; rheumatoid arthritis; rituximab

Domains: Life Sciences [q-bio]

Bertrand Lioger, Soujanya Ratna Edupuganti, Denis Mulleman, Christophe Passot, Celine Desvignes, et al.. Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients. British Journal of Clinical Pharmacology, 2017, 83 (8), pp.1773-1781. ⟨10.1111/bcp.13270⟩. ⟨hal-02425330⟩